Δημοσιεύσεις


  • Optimal Time Interval between Neoadjuvant Platinum-Based Chemotherapy and Interval Debulking Surgery in High-Grade Serous Ovarian Cancer.

Andrikopoulou A, Theofanakis C, Markellos C, Kaparelou M, Koutsoukos K, Apostolidou K, Thomakos N, Haidopoulos D, Rodolakis A, Dimopoulos MA, Zagouri F, Liontos M.

Cancers (Basel). 2023 Jul 6;15(13):3519. doi: 10.3390/cancers15133519.

PMID: 37444629 Free PMC article.

  • Intravenous rituximab and oral cyclophosphamide for the treatment of cancer‑associated retinopathy in a patient with epithelial ovarian cancer: A case report.

Andrikopoulou A, Koutsoukos K, Chatziralli I, Theodossiadis P, Tsivgoulis G, Tzartos J, Anastasakis A, Zagouri F, Dimopoulos MA.

Oncol Lett. 2023 Jun 1;26(1):308. doi: 10.3892/ol.2023.13894. eCollection 2023 Jul.

PMID: 37332336 Free PMC article.

  • Outcomes from treatment of metastatic renal-cell carcinoma following failure of first-line anti-VEGF/VEGFR therapy: real-life evidence on the change of the treatment paradigm.

Bamias A, Zakopoulou R, Tzannis K, Sakellakis M, Koutsoukos K, Kyriazoglou A, Panagiotou A, Armylagos S, Rokas K, Gotzias D, Boulouta A, Bozionelou V, Stravodimos K, Varkarakis I, Mavroudis D, Dimopoulos MA.

Anticancer Drugs. 2023 Mar 1;34(3):413-421. doi: 10.1097/CAD.0000000000001420. Epub 2022 Nov 16.

PMID: 36730619 Clinical Trial.

  • Pembrolizumab in combination with bevacizumab and oral cyclophosphamide in heavily pre-treated platinum-resistant ovarian cancer.

Andrikopoulou A, Liontos M, Skafida E, Koutsoukos K, Apostolidou K, Kaparelou M, Rouvalis A, Bletsa G, Dimopoulos MA, Zagouri F.

Int J Gynecol Cancer. 2023 Apr 3;33(4):571-576. doi: 10.1136/ijgc-2022-003941.

PMID: 36604119

  • Germline and somatic variants in ovarian carcinoma: A next-generation sequencing (NGS) analysis.

Andrikopoulou A, Zografos E, Apostolidou K, Kyriazoglou A, Papatheodoridi AM, Kaparelou M, Koutsoukos K, Liontos M, Dimopoulos MA, Zagouri F.

Front Oncol. 2022 Dec 1;12:1030786. doi: 10.3389/fonc.2022.1030786. eCollection 2022.

PMID: 36531003 Free PMC article.

  • Assessment of Postvaccination Neutralizing Antibodies Response against SARS-CoV-2 in Cancer Patients under Treatment with Targeted Agents.

Zagouri F, Papatheodoridi A, Liontos M, Briasoulis A, Sklirou AD, Skafida E, Fiste O, Markellos C, Andrikopoulou A, Koutsoukos K, Kaparelou M, Gkogkou E, Trougakos IP, Dimopoulos MA, Terpos E.

Vaccines (Basel). 2022 Sep 5;10(9):1474. doi: 10.3390/vaccines10091474.

PMID: 36146552 Free PMC article.

  • Risk for Arterial Thromboembolic Events (ATEs) in Patients with Advanced Urinary Tract Cancer (aUTC) Treated with First-Line Chemotherapy: Single-Center, Observational Study.

Bamias A, Tzannis K, Zakopoulou R, Sakellakis M, Dimitriadis J, Papatheodoridi A, Rallidis L, Halvatsiotis P, Tsiara A, Kaparelou M, Kostouros E, Barbarousi D, Koutsoukos K, Fragiadis E, Dellis AE, Anastasiou I, Stravodimos K, Pinitas A, Papatsoris A, Adamakis I, Varkarakis I, Fragoulis C, Pagoni S, Matsouka C, Skolarikos A, Mitropoulos D, Doumas K, Deliveliotis C, Constantinides C, Dimopoulos MA.

Curr Oncol. 2022 Aug 24;29(9):6077-6090. doi: 10.3390/curroncol29090478.

PMID: 36135047 Free PMC article.

  • SARS-CoV-2 Neutralizing Antibodies Kinetics Postvaccination in Cancer Patients under Treatment with Immune                            Checkpoint Inhibition.

Terpos E, Liontos M, Fiste O, Zagouri F, Briasoulis A, Sklirou AD, Markellos C, Skafida E, Papatheodoridi A, Andrikopoulou A, Koutsoukos K, Kaparelou M, Iconomidou VA, Trougakos IP, Dimopoulos MA.

Cancers (Basel). 2022 Jun 4;14(11):2796. doi: 10.3390/cancers14112796.

PMID: 35681774 Free PMC article.

  • Oncological Patients With Endocrine Complications After Immunotherapy With Checkpoint Inhibitors Present Longer Progression-Free and Overall Survival.

Paschou SA, Liontos M, Eleftherakis-Papaiakovou E, Stefanaki K, Markellos C, Koutsoukos K, Zagouri F, Psaltopoulou T, Dimopoulos MA.

Front Oncol. 2022 Mar 24;12:847917. doi: 10.3389/fonc.2022.847917. eCollection 2022.

PMID: 35402216 Free PMC article.

  • What Has Changed in the Management of Uterine Serous Carcinomas? Two Decades of Experience.

Liontos M, Svarna A, Theofanakis C, Fiste O, Andrikopoulou A, Kaparelou M, Koutsoukos K, Thomakos N, Haidopoulos D, Rodolakis A, Dimopoulos MA, Zagouri F.

Curr Oncol. 2021 Nov 20;28(6):4862-4873. doi: 10.3390/curroncol28060410.

PMID: 34898589 Free PMC article.

  • ERCC1 19007 Polymorphism in Greek Patients with Advanced Urothelial Cancer Treated with Platinum-Based Chemotherapy: Effect of the Changing Treatment Paradigm: A Cohort Study by the Hellenic GU Cancer Group.

Bamias A, Koutsoukos K, Gavalas N, Zakopoulou R, Tzannis K, Dedes N, Boulouta A, Fragkoulis C, Kostouros E, Dellis A, Mitsogiannis I, Adamakis I, Anastasiou I, Skolarikos A, Papatsoris A, Stravodimos K, Ferakis N, Pagoni S, Ntoumas K, Mitropoulos D, Deliveliotis C, Constantinides CA, Dimopoulos MA.

Curr Oncol. 2021 Nov 5;28(6):4474-4484. doi: 10.3390/curroncol28060380.

PMID: 34898581 Free PMC article.

  • BRCA1/2 Mutation Types Do Not Affect Prognosis in Ovarian Cancer Patients.

Liontos M, Zografos E, Zoumpourlis P, Andrikopoulou A, Svarna A, Fiste O, Kunadis E, Papatheodoridi AM, Kaparelou M, Koutsoukos K, Thomakos N, Haidopoulos D, Rodolakis A, Dimopoulos MA, Zagouri F.

Curr Oncol. 2021 Nov 3;28(6):4446-4456. doi: 10.3390/curroncol28060377.

PMID: 34898566 Free PMC article.

  • Neutrophil-to-lymphocyte ratio and chemotherapy response score as prognostic markers in ovarian cancer patients treated with neoadjuvant chemotherapy.

Liontos M, Andrikopoulou A, Koutsoukos K, Markellos C, Skafida E, Fiste O, Kaparelou M, Thomakos N, Haidopoulos D, Rodolakis A, Dimopoulos MA, Zagouri F.

J Ovarian Res. 2021 Nov 1;14(1):148. doi: 10.1186/s13048-021-00902-0.

PMID: 34724958 Free PMC article.

  • Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP Inhibitors.

Liontos M, Terpos E, Markellos C, Zagouri F, Briasoulis A, Katsiana I, Skafida E, Fiste O, Kunadis E, Andrikopoulou A, Kaparelou M, Koutsoukos K, Gavriatopoulou M, Kastritis E, Trougakos IP, Dimopoulos MA.

Vaccines (Basel). 2021 Oct 8;9(10):1148. doi: 10.3390/vaccines9101148.

PMID: 34696256 Free PMC article.

  • Treatment with abiraterone or enzalutamide does not impair immunological response to COVID-19 vaccination in prostate cancer patients.

Liontos M, Terpos E, Kunadis E, Zagouri F, Briasoulis A, Skafida E, Fiste O, Markellos C, Andrikopoulou A, Gumeni S, Kaparelou M, Koutsoukos K, Gavriatopoulou M, Kastritis E, Trougakos IP, Dimopoulos MA.

Prostate Cancer Prostatic Dis. 2022 Mar;25(1):117-118. doi: 10.1038/s41391-021-00455-9. Epub 2021 Oct 9.

PMID: 34628475 Free PMC article.

  • SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors.

Zagouri F, Terpos E, Fiste O, Liontos M, Briasoulis A, Katsiana I, Skafida E, Markellos C, Kunadis E, Andrikopoulou A, Kaparelou M, Koutsoukos K, Gavriatopoulou M, Kastritis E, Trougakos IP, Dimopoulos MA.

Breast. 2021 Dec;60:58-61. doi: 10.1016/j.breast.2021.08.017. Epub 2021 Aug 28.

PMID: 34481366 Free PMC article.

  • MicroRNAs as Potential Predictors of Response to CDK4/6 Inhibitor Treatment.

Andrikopoulou A, Shalit A, Zografos E, Koutsoukos K, Korakiti AM, Liontos M, Dimopoulos MA, Zagouri F.

Cancers (Basel). 2021 Aug 16;13(16):4114. doi: 10.3390/cancers13164114.

PMID: 34439268 Free PMC article. Review.

  • Referral for “Neoadjuvant Chemotherapy” for Muscle-Invasive Bladder Cancer to a Multidisciplinary Board: Patterns, Management and Outcomes.

Dellis A, Zakopoulou R, Kougioumtzopoulou A, Tzannis K, Koutsoukos K, Fragkoulis C, Kostouros E, Papatsoris A, Varkarakis I, Stravodimos K, Boutati E, Pagoni S, Seferlis M, Chrisofos M, Kouloulias V, Ntoumas K, Deliveliotis C, Constantinides C, Dimopoulos MA, Bamias A.

Cancer Manag Res. 2021 Jul 30;13:5941-5955. doi: 10.2147/CMAR.S317500. eCollection 2021.

PMID: 34354376 Free PMC article.

  • Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors.

Terpos E, Zagouri F, Liontos M, Sklirou AD, Koutsoukos K, Markellos C, Briasoulis A, Papanagnou ED, Trougakos IP, Dimopoulos MA.

J Hematol Oncol. 2021 May 31;14(1):86. doi: 10.1186/s13045-021-01099-x.

PMID: 34059088 Free PMC article.

  • The Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma.

Fiste O, Ntanasis-Stathopoulos I, Gavriatopoulou M, Liontos M, Koutsoukos K, Dimopoulos MA, Zagouri F.

Vaccines (Basel). 2021 Apr 22;9(5):422. doi: 10.3390/vaccines9050422.

PMID: 33922362 Free PMC article. Review.

  • Continuing Cancer Therapy through the Pandemic While Protecting Our Patients: Results of the Implementation of Preventive Strategies in a Referral Oncology Unit.

Liontos M, Kastritis E, Markellos C, Migkou M, Eleftherakis-Papaiakovou E, Koutsoukos K, Gavriatopoulou M, Zagouri F, Psaltopoulou T, Terpos E, Dimopoulos MA.

Cancers (Basel). 2021 Feb 12;13(4):763. doi: 10.3390/cancers13040763.

PMID: 33673120 Free PMC article.

  • Clinical perspectives of BET inhibition in ovarian cancer.

Andrikopoulou A, Liontos M, Koutsoukos K, Dimopoulos MA, Zagouri F.

Cell Oncol (Dordr). 2021 Apr;44(2):237-249. doi: 10.1007/s13402-020-00578-6. Epub 2021 Jan 19.

PMID: 33469840 Review.

  • Circulating tumor DNA-based predictive biomarkers in breast cancer clinical trials: a narrative review.

Fiste O, Liontos M, Koutsoukos K, Terpos E, Dimopoulos MA, Zagouri F.

Ann Transl Med. 2020 Dec;8(23):1603. doi: 10.21037/atm-20-1175.

PMID: 33437802 Free PMC article. Review.

  • How we treat endocrine complications of immune checkpoint inhibitors.

Paschou SA, Stefanaki K, Psaltopoulou T, Liontos M, Koutsoukos K, Zagouri F, Lambrinoudaki I, Dimopoulos MA.

ESMO Open. 2021 Feb;6(1):100011. doi: 10.1016/j.esmoop.2020.100011. Epub 2021 Jan 4.

PMID: 33399077 Free PMC article. Review.

  • Clinical Perspectives of ERCC1 in Bladder Cancer.

     Koutsoukos K, Andrikopoulou A, Dedes N, Zagouri F, Bamias A, Dimopoulos MA.

Int J Mol Sci. 2020 Nov 22;21(22):8829. doi: 10.3390/ijms21228829.

PMID: 33266377 Free PMC article. Review.

  • Response of an oncology unit in the midst of the COVID-19 outbreak.

Liontos M, Kastritis E, Migkou M, Koutsoukos K, Eleutherakis-Papaiakovou E, Gavriatopoulou M, Psaltopoulou T, Zagouri F, Terpos E, Dimopoulos MA.

J Oncol Pharm Pract. 2020 Dec;26(8):1947-1952. doi: 10.1177/1078155220967973. Epub 2020 Oct 22.

PMID: 33092498

  • Trastuzumab Deruxtecan (DS-8201a): The Latest Research and Advances in Breast Cancer.

Andrikopoulou A, Zografos E, Liontos M, Koutsoukos K, Dimopoulos MA, Zagouri F.

Clin Breast Cancer. 2021 Jun;21(3):e212-e219. doi: 10.1016/j.clbc.2020.08.006. Epub 2020 Aug 18.

PMID: 32917537 Review.

  • The emerging role of BET inhibitors in breast cancer.

Andrikopoulou A, Liontos M, Koutsoukos K, Dimopoulos MA, Zagouri F.

Breast. 2020 Oct;53:152-163. doi: 10.1016/j.breast.2020.08.005. Epub 2020 Aug 13.

PMID: 32827765 Free PMC article. Review.

  • Secondary Alopecia Neoplastica Mimicking Alopecia Areata following Breast Cancer.

Skafida E, Triantafyllopoulou I, Flessas I, Liontos M, Koutsoukos K, Zagouri F, Dimopoulos AM.

Case Rep Oncol. 2020 Jun 11;13(2):627-632. doi: 10.1159/000507694. eCollection 2020 May-Aug.

PMID: 32774247 Free PMC article.

  • Axitinib as a third or further line of treatment in renal cancer: a single institution experience.

Tsironis G, Liontos M, Kyriazoglou A, Koutsoukos K, Tsiara A, Kaparelou M, Zakopoulou R, Cohen A, Skafida E, Fontara S, Zagouri F, Bamias A, Dimopoulos MA.

BMC Urol. 2020 Jun 2;20(1):60. doi: 10.1186/s12894-020-00618-1.

PMID: 32487200 Free PMC article.

  • Lymphocytic infiltration and Chemotherapy Response Score as prognostic markers in ovarian cancer patients treated with Neoadjuvant chemotherapy.

Liontos M, Sotiropoulou M, Kaparelou M, Tzannis K, Tsironis G, Kyriazoglou A, Tsiara A, Zakopoulou R, Koutsoukos K, Zagouri F, Thomakos N, Haidopoulos D, Rodolakis A, Dimopoulos MA, Bamias A.

Gynecol Oncol. 2020 Jun;157(3):599-605. doi: 10.1016/j.ygyno.2020.03.008. Epub 2020 Mar 12.

PMID: 32173048

  • Metastatic Hepatic Epithelioid Hemangioendothelioma Treated with Olaratumab: A Falling Star Rising?

Kyriazoglou A, Koutsoukos K, Zagouri F, Liontos M, Dimitriadis E, Tiniakos D, Dimopoulos MA.

Ther Clin Risk Manag. 2020 Feb 27;16:141-146. doi: 10.2147/TCRM.S220804. eCollection 2020.

PMID: 32161464 Free PMC article.

  • Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcome-Results from the International Metastatic Renal Cell Carcinoma Database Consortium.

Donskov F, Xie W, Overby A, Wells JC, Fraccon AP, Sacco CS, Porta C, Stukalin I, Lee JL, Koutsoukos K, Yuasa T, Davis ID, Pezaro C, Kanesvaran R, Bjarnason GA, Sim HW, Rathi N, Kollmannsberger CK, Canil CM, Choueiri TK, Heng DYC.

Eur Urol Oncol. 2020 Aug;3(4):530-539. doi: 10.1016/j.euo.2020.01.001. Epub 2020 Feb 6.

PMID: 32037304

  • Outcome of Men With Relapses After Adjuvant Bleomycin, Etoposide, and Cisplatin for Clinical Stage I Nonseminoma.

Fischer S, Tandstad T, Cohn-Cedermark G, Thibault C, Vincenzi B, Klingbiel D, Albany C, Necchi A, Terbuch A, Lorch A, Aparicio J, Heidenreich A, Hentrich M, Wheater M, Langberg CW, Ståhl O, Fankhauser CD, Hamid AA, Koutsoukos K, Shamash J, White J, Bokemeyer C, Beyer J, Gillessen S; Global Germ-Cell Cancer Group.

J Clin Oncol. 2020 Apr 20;38(12):1322-1331. doi: 10.1200/JCO.19.01876. Epub 2019 Dec 26.

PMID: 31877087 Free PMC article.

  • Management of uterine sarcomas and prognostic indicators: real world data from a single-institution.

Kyriazoglou A, Liontos M, Ziogas DC, Zagouri F, Koutsoukos K, Tsironis G, Tsiara A, Kaparelou M, Zakopoulou R, Thomakos N, Haidopoulos D, Papaspyrou I, Rodolakis A, Bamias A, Dimopoulos MA.

BMC Cancer. 2018 Dec 13;18(1):1247. doi: 10.1186/s12885-018-5156-1.

PMID: 30541504 Free PMC article.

  • Patterns of practice and pharmacoeconomic analysis of the management of patients with metastatic renal cell carcinoma (mRCC) in Greece–the CRISIS study. A retrospective analysis by the Hellenic Genitourinary Cancer Group (HGUCG).

Tsironis G, Koutsoukos K, Athanasakis K, Tsiara A, Tzannis K, Gerolympou M, Visvikis A, Oikonomopoulos G, Kollia A, Giannopoulou E, Dimitra M, Kostouros E, Papatsoris A, Dellis A, Stravodimos K, Varkarakis I, Samantas E, Aravantinos G, Kentepozidis N, Christodoulou C, Bozionelou V, Dimopoulos MA, Bamias A.

Expert Rev Pharmacoecon Outcomes Res. 2019 Aug;19(4):491-501. doi: 10.1080/14737167.2019.1546121. Epub 2018 Nov 19.

PMID: 30417707

  • The combination of bevacizumab/temsirolimus after first-line anti-VEGF therapy in advanced renal-cell carcinoma: a clinical and biomarker study.

Bamias A, Karavasilis V, Gavalas N, Tzannis K, Samantas E, Aravantinos G, Koutras A, Gkerzelis I, Kostouros E, Koutsoukos K, Zagouri F, Fountzilas G, Dimopoulos MA.

Int J Clin Oncol. 2019 Apr;24(4):411-419. doi: 10.1007/s10147-018-1361-9. Epub 2018 Oct 29.

PMID: 30374686 Clinical Trial.

  • Breakthroughs in the treatment of advanced squamous-cell NSCLC: not the neglected sibling anymore?

Tsironis G, Ziogas DC, Kyriazoglou A, Lykka M, Koutsoukos K, Bamias A, Dimopoulos MA.

Ann Transl Med. 2018 Apr;6(8):143. doi: 10.21037/atm.2018.02.18.

PMID: 29862232 Free PMC article. Review.

  • Real-world experience of everolimus as second-line treatment in metastatic renal cell cancer after failure of pazopanib.

Koutsoukos K, Bamias A, Tzannis K, Espinosa Montaño M, Bozionelou V, Christodoulou C, Stefanou D, Kalofonos H, Duran I, Papazisis K.

Onco Targets Ther. 2017 Oct 6;10:4885-4893. doi: 10.2147/OTT.S141260. eCollection 2017.

PMID: 29062235 Free PMC article.

  • Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the Targeted Therapy Era: Results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC).

Yip SM, Ruiz Morales JM, Donskov F, Fraccon A, Basso U, Rini BI, Lee JL, Bjarnason GA, Sim HW, Beuselinck B, Kanesvaran R, Brugarolas J, Koutsoukos K, Fu SYF, Yuasa T, Davis I, Alva A, Kollmannsberger C, Choueiri TK, Heng DYC.

Kidney Cancer. 2017 Jul 26;1(1):41-47. doi: 10.3233/KCA-160002.

PMID: 30334003 Free PMC article.

  • Expression and prognostic significance of VEGF and mTOR pathway proteins in metastatic renal cell carcinoma patients: a prognostic immunohistochemical profile for kidney cancer patients.

Liontos M, Trigka EA, Korkolopoulou P, Tzannis K, Lainakis G, Koutsoukos K, Kostouros E, Lykka M, Papandreou CN, Karavasilis V, Christodoulou C, Papatsoris A, Skolarikos A, Varkarakis I, Adamakis I, Alamanis C, Stravodimos K, Mitropoulos D, Deliveliotis C, Constantinidis CA, Saetta A, Patsouris E, Dimopoulos MΑ, Bamias A.

World J Urol. 2017 Mar;35(3):411-419. doi: 10.1007/s00345-016-1890-7. Epub 2016 Jul 9.

PMID: 27395374

  • The Development of an Angiogenic Protein “Signature” in Ovarian Cancer Ascites as a Tool for Biologic and Prognostic Profiling.

Trachana SP, Pilalis E, Gavalas NG, Tzannis K, Papadodima O, Liontos M, Rodolakis A, Vlachos G, Thomakos N, Haidopoulos D, Lykka M, Koutsoukos K, Kostouros E, Terpos E, Chatziioannou A, Dimopoulos MA, Bamias A.

PLoS One. 2016 Jun 3;11(6):e0156403. doi: 10.1371/journal.pone.0156403. eCollection 2016.

PMID: 27258020 Free PMC article.

  • Novel therapies for advanced squamous cell carcinoma of the lung.

Koutsoukos K, Mountzios G.

Future Oncol. 2016 Mar;12(5):659-67. doi: 10.2217/fon.15.358. Epub 2016 Feb 1.

PMID: 26880383 Review.

  • Utilization of Systemic Chemotherapy in Advanced Urothelial Cancer: A Retrospective Collaborative Study by the Hellenic Genitourinary Cancer Group (HGUCG).

Bamias A, Peroukidis S, Stamatopoulou S, Tzannis K, Koutsoukos K, Andreadis C, Bozionelou V, Pistalmatzian N, Papatsoris A, Stravodimos K, Varthalitis I, Karamouzis M, Milaki G, Agorastos A, Kentepozidis N, Androulakis N, Bompolaki I, Kalofonos H, Mavroudis D, Dimopoulos MA.

Clin Genitourin Cancer. 2016 Apr;14(2):e153-9. doi: 10.1016/j.clgc.2015.09.009. Epub 2015 Sep 25.

PMID: 26437909

  • Two cycles of adjuvant carboplatin in stage I seminoma: 8-year experience by the Hellenic Cooperative Oncology Group (HECOG).

Koutsoukos K, Tzannis K, Christodoulou C, Karavasilis V, Bakoyiannis C, Makatsoris T, Papandreou CN, Pectasides D, Dimopoulos MA, Bamias A.

World J Urol. 2016 Jun;34(6):853-7. doi: 10.1007/s00345-015-1695-0. Epub 2015 Sep 26.

PMID: 26410826

  • Autoimmune hemolytic anemia and autoimmune thrombocytopenia at diagnosis and during follow-up of Hodgkin lymphoma.

Dimou M, Angelopoulou MK, Pangalis GA, Georgiou G, Kalpadakis C, Pappi V, Tsopra O, Koutsoukos K, Zografos E, Boutsikas G, Moschogianni M, Vardounioti I, Petevi K, Karali V, Kanellopoulos A, Ntalageorgos T, Yiakoumis X, Bartzis V, Bitsani A, Pessach E, Efthimiou A, Korkolopoulou P, Rassidakis G, Kyrtsonis MC, Patsouris E, Meletis J, Panayiotidis P, Vassilakopoulos TP.

Leuk Lymphoma. 2012 Aug;53(8):1481-7. doi: 10.3109/10428194.2012.660628. Epub 2012 Apr 2.

PMID: 22280533

  • Heat shock protein 90 (hsp90) expression and breast cancer.

Zagouri F, Bournakis E, Koutsoukos K, Papadimitriou CA.

Pharmaceuticals (Basel). 2012 Sep 12;5(9):1008-20. doi: 10.3390/ph5091008.

PMID: 24280702 Free PMC article.